Increased Phospho-AKT in Blood Cells from LRRK2 G2019S Mutation Carriers.


Journal

Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449

Informations de publication

Date de publication:
11 2022
Historique:
revised: 15 07 2022
received: 28 03 2022
accepted: 29 07 2022
pubmed: 6 8 2022
medline: 26 10 2022
entrez: 5 8 2022
Statut: ppublish

Résumé

The purpose of this study was to investigate whether  differential phosphorylation states of blood markers can identify patients with LRRK2 Parkinson's disease (PD). We assessed phospho(P)-Ser-935-LRRK2 and P-Ser-473-AKT levels in peripheral blood cells from patients with G2019S LRRK2-associated PD (L2PD, n = 31), G2019S LRRK2 non-manifesting carriers (L2NMC, n = 26), idiopathic PD (iPD, n = 25), and controls (n = 40, total n = 122). We found no differences at P-Ser-935-LRRK2 between groups but detected a specific increase of P-Ser-473-AKT levels in all G2019S carriers, either L2PD or L2NMC, absent in iPD. Although insensitive to LRRK2 inhibition, our study identifies P-Ser-473-AKT as an endogenous candidate biomarker for peripheral inflammation in G2019S carriers using accessible blood cells. ANN NEUROL 2022;92:888-894.

Identifiants

pubmed: 35929078
doi: 10.1002/ana.26469
pmc: PMC9827833
doi:

Substances chimiques

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 EC 2.7.11.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1
Biomarkers 0
LRRK2 protein, human EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

888-894

Informations de copyright

© 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Références

J Neuroinflammation. 2022 May 22;19(1):113
pubmed: 35599331
J Immunol. 2004 Jun 15;172(12):7583-91
pubmed: 15187138
J Neurosci. 2008 Dec 31;28(53):14363-71
pubmed: 19118169
J Transl Med. 2019 Jan 22;17(1):37
pubmed: 30670047
Nat Rev Neurol. 2020 Feb;16(2):97-107
pubmed: 31980808
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Brain Res Dev Brain Res. 1999 Nov 18;117(2):145-52
pubmed: 10567732
Exp Neurobiol. 2019 Apr;28(2):134-145
pubmed: 31138985
Cell. 2017 Apr 20;169(3):381-405
pubmed: 28431241
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7
pubmed: 16269541
J Neurol Sci. 2019 Jul 15;402:121-130
pubmed: 31129265
J Leukoc Biol. 2010 May;87(5):895-904
pubmed: 20103769
Mov Disord. 2006 Nov;21(11):1954-9
pubmed: 16991141
Biochem Soc Trans. 2019 Dec 20;47(6):1581-1595
pubmed: 31769472
Mol Neurobiol. 2018 Oct;55(10):7728-7742
pubmed: 29460266
Mov Disord. 2022 May;37(5):1004-1015
pubmed: 35049090
Nat Genet. 2010 Sep;42(9):781-5
pubmed: 20711177
Sci Rep. 2019 Mar 14;9(1):4515
pubmed: 30872638
Cell Death Differ. 2010 Feb;17(2):324-35
pubmed: 19745829
Biochem J. 2018 Jan 2;475(1):23-44
pubmed: 29127255
Biochim Biophys Acta Mol Cell Res. 2020 Nov 12;1868(2):118907
pubmed: 33189783
J Parkinsons Dis. 2020;10(2):623-629
pubmed: 32007961
EMBO J. 2020 Oct 15;39(20):e104862
pubmed: 32853409
Neurosci Lett. 2009 Dec 18;467(1):30-5
pubmed: 19800394
Hum Mol Genet. 2016 May 15;25(10):1965-1978
pubmed: 26931464
J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):626-8
pubmed: 17210620
Circ Res. 2012 Oct 26;111(10):1297-307
pubmed: 22927331
Biochem J. 2010 Sep 15;430(3):405-13
pubmed: 20659021
Nat Rev Immunol. 2022 Nov;22(11):657-673
pubmed: 35246670
Cell Cycle. 2009 Sep 1;8(17):2789-93
pubmed: 19652548
J Med Chem. 2017 Apr 13;60(7):2983-2992
pubmed: 28245354
Cell Stress Chaperones. 2021 Nov;26(6):871-887
pubmed: 34386944
Curr Neuropharmacol. 2016;14(3):214-25
pubmed: 26517051
Mov Disord. 2016 Jun;31(6):889-97
pubmed: 26917005
Neurotox Res. 2019 Apr;35(3):775-795
pubmed: 30707354
J Parkinsons Dis. 2022;12(s1):S29-S43
pubmed: 35661019
Neurology. 2014 Aug 5;83(6):568-9
pubmed: 25008396
Hum Mol Genet. 2015 Sep 1;24(17):4879-900
pubmed: 26056228
Front Neurosci. 2020 Jun 16;14:527
pubmed: 32612495
Cell Physiol Biochem. 2013;31(6):795-804
pubmed: 23735868
J Neuroinflammation. 2016 May 24;13(1):122
pubmed: 27220776
Hum Mol Genet. 2013 Mar 1;22(5):1039-49
pubmed: 23223016
Acta Neuropathol. 2021 Sep;142(3):475-494
pubmed: 34125248
Mov Disord. 2020 Nov;35(11):2095-2100
pubmed: 32652692
Hum Mol Genet. 2014 Nov 1;23(21):5649-58
pubmed: 24916379

Auteurs

Alicia Garrido (A)

Parkinson Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.

Leticia Pérez-Sisqués (L)

Department of Biomedicine, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain.
Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.

Cristina Simonet (C)

Parkinson Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.

Genís Campoy-Campos (G)

Department of Biomedicine, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain.
Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.

Júlia Solana-Balaguer (J)

Department of Biomedicine, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain.
Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.

Núria Martín-Flores (N)

Department of Biomedicine, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain.
Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.

Manel Fernández (M)

Parkinson Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.

Marta Soto (M)

Parkinson Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.

Donina Obiang (D)

Parkinson Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.

Ana Cámara (A)

Parkinson Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.

Francesc Valldeoriola (F)

Parkinson Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.

Esteban Muñoz (E)

Parkinson Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.

Yaroslau Compta (Y)

Parkinson Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.

Esther Pérez-Navarro (E)

Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.
Department of Biomedicine, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain.
Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.

Jordi Alberch (J)

Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.
Department of Biomedicine, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain.
Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.

Eduardo Tolosa (E)

Parkinson Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.

María-José Martí (MJ)

Parkinson Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.

Mario Ezquerra (M)

Parkinson Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.

Cristina Malagelada (C)

Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.
Department of Biomedicine, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain.
Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.

Rubén Fernández-Santiago (R)

Parkinson Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain.
Department of Biomedicine, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH